Clinical trials
Lymphoma, B-Cell trials in Spain
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
56 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2006 | 2 |
| 2007 | 2 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 2 |
| 2018 | 3 |
| 2019 | 7 |
| 2020 | 2 |
| 2021 | 7 |
| 2022 | 6 |
| 2023 | 2 |
| 2024 | 6 |
| 2025 | 2 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 20 |
| Active, not recruiting | 16 |
| Recruiting | 13 |
| Terminated | 5 |
| Unknown status | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Loxo Oncology, Inc. | 5 |
| Novartis Pharmaceuticals | 5 |
| Hoffmann-La Roche | 4 |
| AstraZeneca | 3 |
| Celgene | 3 |
| Regeneron Pharmaceuticals | 3 |
| Instituto de Investigación Biomédica de Salamanca | 2 |
| Janssen Research & Development, LLC | 2 |
| Kite, A Gilead Company | 2 |
| Millennium Pharmaceuticals, Inc. | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lymphoma, B-Cell | 56 |
| Lymphoma, Non-Hodgkin | 23 |
| Lymphoma, Large B-Cell, Diffuse | 19 |
| Lymphoma | 13 |
| Recurrence | 12 |
| Lymphoma, Follicular | 9 |
| Lymphoma, Mantle-Cell | 9 |
| Neoplasms | 8 |
| Hematologic Diseases | 7 |
| Lymphoma, B-Cell, Marginal Zone | 7 |
Trials
Showing 51 to 56 of 56. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.